Factor 8 SHL denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for factor 8 shl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Factor VIII (SHL) as Not FDA-Approved

A not-FDA-approved denial from Blue Cross Blue Shield means their claim system flagged the specific extended half-life (SHL) Factor VIII product as either lacking FDA approval for the indication submitted, or as being used in a way that falls outside the scope of its approved labeling (an off-label use).

This denial type has two very different paths depending on the facts:

1. If the product IS FDA-approved for your indication: this denial is likely a coding or documentation error and is highly overturnable. You need to submit the FDA approval documentation directly. 2. If the use IS off-label: the appeal is harder but still viable. Federal law (particularly for cancer and other serious conditions) and many state laws require insurers to cover medically necessary off-label uses supported by recognized compendia or peer-reviewed literature.

## Federal Appeal Rights

• ACA §2719: most not-FDA-approved denials qualify for independent external review, particularly where the denial involves a coverage determination about generally accepted standards of medical practice.
• ERISA §503: employer-plan members have full-and-fair internal review rights.
• You generally have approximately four months from the denial date to request external review.
• Expedited review: available when delay poses serious health risk; request from your hematologist.

## Concrete Appeal Timeline

1. Confirm FDA approval status for the specific product and the exact indication billed — review the product's current prescribing information. 2. If approved: submit the prescribing information and denial rebuttal immediately. 3. If off-label: have your hematologist document compendia support and clinical rationale before filing.

## Documentation to Gather

• FDA prescribing information: the full current FDA-approved labeling for the specific Factor VIII SHL product, clearly showing the approved indication.
• Diagnosis records: hematology records confirming your diagnosis maps to the approved indication.
• Correct billing codes: verify that the HCPCS/NDC code submitted matches the approved product — coding mismatches frequently generate these denials.
• Prescriber letter (off-label pathway): if use is off-label, a letter from your hematologist citing support in recognized drug compendia (e.g., Micromedex, Clinical Pharmacology) or peer-reviewed hematology literature, and explaining why on-label alternatives are insufficient.
• State law protections: your attorney or patient advocate should check whether your state has a statute requiring coverage of medically necessary off-label use of FDA-approved drugs.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Evidence | |---|---| | Product not FDA-approved | [Cite FDA approval letter / product label indication section] | | Use outside approved labeling | [Compendia citation + hematologist letter; state law if applicable] | | Coding mismatch | [Correct HCPCS/NDC with explanation] |

Always obtain and cite the current FDA-approved prescribing information directly. Verify the exact language in BCBS's published coverage policy for Factor VIII products, as their definition of "not-approved" may include specific off-label criteria that your documentation must address.